ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

Why Nivolumab is on this study

  • The record lists it as a treatment, written “Relatlimab + Nivolumab”.
  • Claude Opus 5.5 judged it observed: patients on it are followed, not assigned it by the study. Nov 2, 2026, 5:24 AM UTC“Immune responses with relatlimab in melanoma”
  • The role rule says the same.
  • So Nivolumab's page lists this study under “Observed”.
5 links0 made here, not in the record6 judgments2 judges (the rules as one: Rule based)1 record change seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.gov
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT07223411Opdualag vs.Cemiplimab/Fianlimab inRelation to theImmunological Response inTumor and Peripheral Bloodin Unresectable orMetastatic MelanomaJohn KirkwoodrecruitingRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Nov 19 · ClinicalTrials.gov record · Version of 2026-11-19Version of 2026-11-19CONDITIONSMelanomaNo longer in the registry's filing›As of now · Rule based · Main conditionMain conditionDRUGSFianlimabEntry “Fianlimab + Cemiplimab”, read …›Nov 18 · Rule based · ExposureExposureCemiplimabEntry “Fianlimab + Cemiplimab”, read …›Nov 18 · Rule based · ExposureExposureRelatlimabEntry “Relatlimab + Nivolumab”, read …›Nov 18 · Rule based · ExposureExposureNivolumabEntry “Relatlimab + Nivolumab”, read …›Nov 2 · Claude Opus 5.5 · ExposureNov 18 · Rule based · ExposureExposure

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

All judgments on this study

WhenLinkJudgeDecisionState
1 version of the record seen on ClinicalTrials.gov, Nov 19 · changes seen, not judgments
Nov 2NivolumabClaude Opus 5.5ExposureCurrent
Nov 18FianlimabRule based · role ruleExposureCurrent
Nov 18CemiplimabRule based · role ruleExposureCurrent
Nov 18RelatlimabRule based · role ruleExposureCurrent
Nov 18NivolumabRule based · role ruleExposureAgrees
As of nowMelanomaRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.